Evidence map›Paper›PMID 28873511›Full record

Trial reportGut and liver2018

Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial.

Jian Zhang, Samei Lv, Xiaojing Liu, Bin Song, Liping Shi

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut and liver, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05003947 (Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Inflammatory Bowel Disease), which is not on this map. Cited by 89 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 6 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05003947 phase1recruitingnot on this mapstarted 2022, after this paper: background citation

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Inflammatory Bowel Disease

TypeinterventionalSponsorThe Foundation for Orthopaedics and Regenerative MedicineRan2022 to 2025Enrolled15ConditionsInflammatory Bowel DiseasesArmsAlloRx
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 6 syntheses or guidelines pooled it, 178 citations in OpenAlex.

  1. Pooled it
  2. The Efficacy of Stem Cells in Wound Healing: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jian ZhangThe Second Department of Gastroenterology, Shaanxi Provincial People's Hospital, Xi'an, China.
Samei LvThe Second Department of Gastroenterology, Shaanxi Provincial People's Hospital, Xi'an, China.
Xiaojing LiuDepartment of Infectious Diseases, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Bin SongThe Second Department of General Surgery, Shaanxi Provincial People's Hospital, Xi'an, China.
Liping ShiThe Second Department of Gastroenterology, Shaanxi Provincial People's Hospital, Xi'an, China.
Shanxi Medical University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsStem cell therapy has been applied to treat a variety of autoimmune diseases, including Crohn's disease (CD), but few studies have examined the use of umbilical cord mesenchymal stem cells (UC-MSCs). This trial sought to investigate the efficacy and safety of UC-MSCs for the treatment of CD.

methodsEighty-two patients who had been diagnosed with CD and had received steroid maintenance therapy for more than 6 months were included in this study. Forty-one patients were randomly selected to receive a total of four peripheral intravenous infusions of 1×10

resultsTwelve months after treatment, the CDAI, HBI, and corticosteroid dosage had decreased by 62.5±23.2, 3.4±1.2, and 4.2±0.84 mg/day, respectively, in the UC-MSC group and by 23.6±12.4, 1.2±0.58, and 1.2±0.35 mg/day, respectively, in the control group (p＜0.01, p＜0.05, and p＜0.05 for UC-MSC vs control, respectively). Four patients developed a fever after cell infusion. No serious adverse events were observed.

conclusionsUC-MSCs were effective in the treatment of CD and produced mild side effects.

Indexed as

AdultCord Blood Stem Cell TransplantationCrohn DiseaseFemaleHumansInfusions, IntravenousMaleMesenchymal Stem Cell TransplantationTreatment OutcomeYoung AdultAutoimmuneCellular therapyCrohn diseaseMesenchymal stromal cellsUmbilical cord

Identifiers

PMID28873511
PMCPMC5753687
OpenAlexW2751308524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.